Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to ...

A novel PET imaging approach has revealed distinct patterns of brain inflammation in patients with progressive apraxia of ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

The first clinical guideline on the use of blood biomarker tests could help clinicians choose the most appropriate test to ...

Traditionally, the diagnosis of Alzheimer’s disease has been based on informant interviews and clinical assessments of memory, cognition, behaviour, and mood. To increase diagnostic confidence, ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai presented the latest findings on lecanemab (Leqembi®) at the Alzheimer's Association International ...

Technology Networks recently spoke with Cristiano Tunesi to learn more about how cerebrospinal fluid biomarkers are ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

At June 30, 2025, the Company's cash and cash equivalents were $695.6 million, after payment of $276.4 million for the Evergreen Theragnostics, Inc. (“Evergreen”) acquisition, which closed early in ...

Neurorehabilitation: Transforming lives via interdisciplinary approach for atypical Parkinsonism: Dr. Vignesh Srinivasan & Dr. Poovarasan Wednesday, August 6, 2025, 08:00 Hrs [IST ...

The FDA cleared the use of the first approved blood test that can help diagnose Alzheimer’s disease. Learn more from U of U ...